Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024
23 Mayo 2024 - 12:00PM
Oxurion Announces Results on the Annual Shareholders’ Meeting of 16
May 2024
Oxurion Announces Results on the Annual
Shareholders’ Meeting of 16 May 2024
Leuven, BELGIUM – 23 May, 2024 – 07.00
PM CET – Oxurion NV (Euronext Brussels: OXUR), a
biopharmaceutical company headquartered in Leuven, held its annual
shareholders’ meeting on May 16, 2024. The shareholders approved
all items on the agenda of the annual shareholders’ meeting.
All documents pertaining to the annual
shareholders' meeting held on May 16, 2024, can be consulted on
Oxurion’s website Oxurion/shareholders.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in
developing next-generation standard of care ophthalmic therapies
for the treatment of retinal disease. Oxurion is based in Leuven,
Belgium. More information is available at www.oxurion.com.
Please contact for additional information:
Oxurion NVPascal GhosonChief Executive
Officerpascal.ghoson@oxurion.com |
Backstage CommunicationJurgen
VluijmansPartnerjurgen@backstagecom.be |
Oxurion NV (EU:OXUR)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Oxurion NV (EU:OXUR)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024